Oncovin

(Vincristine)

ApprovedSmall molecule

Vincristine is a chemotherapy drug used to treat various cancers, including leukemia, lymphoma, and some solid tumors, by stopping cancer cells from dividing and growing.[2] Oncovin is currently approved and in use across 58 indications[4].[1]

Oncovin is one of 765 small molecule programs targeting Glioma. It is currently in Approved.

Indications

436

Total Trials

Active Trials

764

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

GliomaActive, not recruiting

Childhood Acute Lymphoblastic LeukemiaActive, not recruiting

EpendymomaActive, not recruiting

HemangiomaActive, not recruiting

Non-Hodgkins LymphomaApproved

Adult Acute Lymphoblastic LeukemiaActive, not recruiting

Primitive Neuroectodermal TumorActive, not recruiting

MacroglobulinemiaActive, not recruiting

T-Cell Acute Lymphoblastic LeukemiaActive, not recruiting

Lymphoblastic LymphomaApproved

GliomaPhase 2

Active, not recruiting

Childhood Acute Lymphoblastic LeukemiaPhase 1

Active, not recruiting

EpendymomaPhase 3

Active, not recruiting

HemangiomaPhase 2

Active, not recruiting

Non-Hodgkins LymphomaApproved

Approved

Adult Acute Lymphoblastic LeukemiaPhase 3

Active, not recruiting

Primitive Neuroectodermal TumorPhase 2

Active, not recruiting

MacroglobulinemiaPhase 2

Active, not recruiting

T-Cell Acute Lymphoblastic LeukemiaPhase 3

Active, not recruiting

Lymphoblastic LymphomaApproved

Approved

Showing 10 of 58 indications

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Oncovin

Eli Lilly

Approved

102 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Oncaspar

SServier

Preclinical

15 4

Zofran

Novartis

Preclinical

2 5

Norvir

AbbVie

Preclinical

1 6

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 7

Tafasitamab

Incyte

Preclinical

7 8

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 9

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Recruiting

Neuroblastoma

NCT01704716

Phase 3Active, not recruiting

B-Cell Acute Lymphoblastic Leukemia

NCT02101853

Active, not recruiting

Infants

NCT05359237

Q4 2026

Phase 1/2Recruiting

Lenalidomide

NCT04432714

Phase 2Recruiting

Acute Lymphoblastic Leukemia

NCT02981628

Phase 3Recruiting

Lymphoma

NCT04638790

Clinical

Trials by Indication[1]

Lymphoma45 trials

Treatment for Classical Hodgkin Lymphoma in Children and Adolescents

Recruiting·GGALIA AVRAHAMI·N/A·NCT02797717·2,200 enrolled

DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

Unknown status·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT03837873·118 enrolled

Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma

Recruiting·SStichting Hemato-Oncologie voor Volwassenen Nederland·Phase 3·NCT06220032·324 enrolled

Show 42 more trials

Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors

Active, not recruiting·SSun Yat-sen University·Phase 1·NCT05620862·68 enrolled

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01445535·15 enrolled

Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas

Withdrawn·NNational Cancer Institute (NCI)·Phase 1/2·NCT02228512

Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00290433·55 enrolled

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Suspended·—·Phase 2·NCT06692452·24 enrolled

A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma

Completed·LLymphoma Study Association·Phase 2·NCT00169156·27 enrolled

Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00299182·50 enrolled

A Phase I/II Trial of VR-CHOP in Lymphoma Patients

Completed·EEmory University·Phase 1/2·NCT00634179·37 enrolled

Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00217425·46 enrolled

A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

Recruiting·UUniversity of Rochester·Phase 2·NCT03758989·40 enrolled

CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma

Unknown status·RRuijin Hospital·Phase 4·NCT01746992·200 enrolled

Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

Terminated·EECOG-ACRIN Cancer Research Group·Phase 2·NCT01390584·6 enrolled

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Withdrawn·FFate Therapeutics·Phase 1·NCT05934097

Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma

Completed·WWeill Medical College of Cornell University·Phase 1/2·NCT01004991·14 enrolled

Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)

Terminated·RRush University Medical Center·Phase 2·NCT02531308·5 enrolled

MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

Withdrawn·NNational Cancer Institute (NCI)·Phase 1/2·NCT01415765

A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT02529852·59 enrolled

A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma

Completed· Roche logo

Roche·Phase 1·NCT00825149·137 enrolled

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT03755804·232 enrolled

Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00274924·100 enrolled

Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma

Terminated·—·Phase 2·NCT00126191·10 enrolled

PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00054665·50 enrolled

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Recruiting·AAIDS Malignancy Consortium·Phase 1·NCT04139304·15 enrolled

BV-AVD-R Treatment Children Hodgkin's Lymphoma

Unknown status·—·Phase 2·NCT06201507·44 enrolled

Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma

Completed·FFondazione Michelangelo·Phase 3·NCT01251107·331 enrolled

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

Terminated· Bayer logo

Bayer·Phase 3·NCT02626455·551 enrolled

Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

Not yet recruiting·—·Phase 1·NCT07278856·20 enrolled

Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.

Unknown status·PPETHEMA Foundation·Phase 2·NCT05049473·100 enrolled

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma

Active, not recruiting· Genmab logo

Genmab·Phase 1/2·NCT05201248·49 enrolled

Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00088881·62 enrolled

Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

Terminated· Gilead logo

Gilead·Phase 1/2·NCT02568683·10 enrolled

BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas

Enrolling by invitation·NN.N. Petrov National Medical Research Center of Oncology·Phase 3·NCT07258680·114 enrolled

R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00809341·27 enrolled

Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma

Suspended·HHenan Cancer Hospital·Phase 2·NCT04668365·59 enrolled

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

Completed· Roche logo

Roche·Phase 1/2·NCT03677141·117 enrolled

A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma

Completed· Roche logo

Roche·Phase 3·NCT01200758·410 enrolled

A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

Terminated· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT02703272·72 enrolled

Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy

Completed·UUniversity College, London·Phase 2·NCT01679119·129 enrolled

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine

Completed· Takeda logo

Takeda·Phase 1/2·NCT01397825·45 enrolled

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

Completed· Pfizer logo

Pfizer·Phase 3·NCT01777152·452 enrolled

Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

Completed·UUniversity of Nebraska·Phase 2·NCT01336933·34 enrolled

First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)

Recruiting·SState Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia·Phase 3·NCT04638790·300 enrolled

Acute Lymphoblastic Leukemia35 trials

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02143414·53 enrolled

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

Recruiting·UUniversity of Washington·Phase 2·NCT07224100·33 enrolled

LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia

Completed·PPETHEMA Foundation·Phase 4·NCT00526409·40 enrolled

Show 32 more trials

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

Active, not recruiting·—·Phase 3·NCT03020030·560 enrolled

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT05032183·4 enrolled

LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive

Completed·PPETHEMA Foundation·Phase 4·NCT00526305·100 enrolled

Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia

Terminated·EEhab L Atallah·Phase 1·NCT01887587·5 enrolled

German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·GGoethe University·Phase 4·NCT00198978·377 enrolled

Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT00763763·55 enrolled

Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)

Completed·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1/2·NCT00440726·31 enrolled

Ma-Spore ALL 2020 Study

Recruiting·NNational University Hospital, Singapore·Phase 2·NCT06336395·500 enrolled

Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia

Completed·AAssociazione Italiana Ematologia Oncologia Pediatrica·Phase 3·NCT00613457·2,039 enrolled

Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia

Completed·SSteven E. Coutre·Phase 1·NCT00313079·9 enrolled

PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Active, not recruiting·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1/2·NCT03817320·24 enrolled

PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

Completed·PPETHEMA Foundation·Phase 4·NCT00494897·374 enrolled

Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00390793·107 enrolled

Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab

Completed·JJohann Wolfgang Goethe University Hospital·Phase 4·NCT00199004·60 enrolled

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02003222·488 enrolled

Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

Completed·PPETHEMA Foundation·Phase 4·NCT02036489·107 enrolled

Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT02420717·11 enrolled

Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Completed·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT02523976·30 enrolled

Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00905034·37 enrolled

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Recruiting·SSt. Jude Children's Research Hospital·Phase 4·NCT06289673·850 enrolled

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Recruiting·CChildren's Oncology Group·Phase 2·NCT02981628·80 enrolled

Treatment of Acute Lymphoblastic Leukemia in Children

Completed·—·Phase 3·NCT00165178·498 enrolled

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT04752163·17 enrolled

Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03147612·22 enrolled

Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00262925·12 enrolled

Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)

Terminated·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1·NCT00928200·1 enrolled

Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

Completed·GGoethe University·Phase 3·NCT02881086·1,023 enrolled

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)

Completed·GGoethe University·Phase 4·NCT00199069·720 enrolled

Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study

Unknown status·NNational University Hospital, Singapore·Phase 4·NCT02894645·500 enrolled

BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients

Not yet recruiting·RRuijin Hospital·Phase 2·NCT07301138·23 enrolled

Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Terminated· Sanofi logo

Sanofi·Phase 2·NCT03860844·67 enrolled

Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)

Unknown status·JJohann Wolfgang Goethe University Hospital·Phase 2·NCT00199186

Diffuse Large B-Cell Lymphoma18 trials

Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma

Completed·SSamsung Medical Center·Phase 2·NCT02670616·24 enrolled

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Suspended·FFavrille·Phase 3·NCT00324831·480 enrolled

Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Completed· Takeda logo

Takeda·Phase 2·NCT01040871·164 enrolled

Show 15 more trials

Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma

Recruiting·LLi Zhiming·Phase 2·NCT05422066·50 enrolled

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03003520·46 enrolled

A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Completed· Roche logo

Roche·Phase 2·NCT04660799·50 enrolled

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04978584·62 enrolled

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Completed· Roche logo

Roche·Phase 1/2·NCT02596971·91 enrolled

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Terminated· Pfizer logo

Pfizer·Phase 2·NCT02855359·24 enrolled

The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma

Unknown status·WWuhan University·Phase 3·NCT02449278·120 enrolled

R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma

Terminated·LLymphoma Study Association·Phase 3·NCT00135499·138 enrolled

Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma

Completed·LLund University Hospital·Phase 1/2·NCT01622439·50 enrolled

Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Terminated· Pfizer logo

Pfizer·Phase 2·NCT01925612·87 enrolled

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01855750·838 enrolled

Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02285062·570 enrolled

Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.

Completed·GGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea·Phase 2·NCT01848132·121 enrolled

A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

Active, not recruiting· Roche logo

Roche·Phase 3·NCT03274492·1,000 enrolled

Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma

Completed·GGruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie·Phase 2·NCT00556127·94 enrolled

Mantle Cell Lymphoma8 trials

R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma

Completed·UUniversity of Miami·Phase 2·NCT00450801·22 enrolled

Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years

Completed·FFrench Innovative Leukemia Organisation·Phase 2·NCT00285389·39 enrolled

EDOCH Alternating With DHAP for New Diagnosed Younger MCL

Completed·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 4·NCT02858804·55 enrolled

Show 5 more trials

Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00477412·107 enrolled

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02427620·131 enrolled

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

Completed· Teva logo

Teva·Phase 3·NCT00877006·447 enrolled

S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00041132·56 enrolled

Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00433537·77 enrolled

Treatment7 trials

Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors

Terminated·TTufts Medical Center·Phase 3·NCT01014767·27 enrolled

LAL-BR/2001: Study Treatment to Low Risk ALL

Completed·PPETHEMA Foundation·Phase 4·NCT00526175·150 enrolled

Genotype-guided Treatment in DLBCL

Recruiting·RRuijin Hospital·Phase 3·NCT05351346·1,100 enrolled

Show 4 more trials

A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors

Terminated·—·Phase 2·NCT02110069·4 enrolled

Treatment of Tumors of the Choroid Plexus Epithelium

Terminated·MM.D. Anderson Cancer Center·Phase 3·NCT00500890·2 enrolled

Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZL

Active, not recruiting·—·Phase 2·NCT07480863·65 enrolled

International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry

Active, not recruiting·—·N/A·NCT01464606·156 enrolled

55 more indications

Follicular Lymphoma6 trials

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT06911502·400 enrolled

An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

Completed· Roche logo

Roche·Phase 4·NCT03817853·114 enrolled

A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients

Completed·UUniversity of Liverpool·Phase 3·NCT01303887·680 enrolled

Show 3 more trials

Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06704555·20 enrolled

Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients

Completed· GSK logo

GSK·Phase 2·NCT00494780·59 enrolled

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Withdrawn·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 3·NCT06313996

Leukemia6 trials

EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma

Completed·WWashington University School of Medicine·Phase 1/2·NCT01000285·18 enrolled

Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00038610·54 enrolled

Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

Active, not recruiting·UUniversity Hospital Muenster·Phase 3·NCT03206671·650 enrolled

Show 3 more trials

CINJALL: Treatment for Children With Acute Lymphocytic Leukemia

Completed·RRutgers, The State University of New Jersey·Phase 2·NCT00176462·60 enrolled

Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00669877·56 enrolled

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05645718·27 enrolled

Medulloblastoma4 trials

Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma

Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT04402073·20 enrolled

Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT02212574·6 enrolled

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

Recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT05535166·130 enrolled

Show 1 more trial

Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma

Terminated·—·Phase 2·NCT00031590·30 enrolled

Chemotherapy4 trials

Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)

Completed·MM.D. Anderson Cancer Center·N/A·NCT00410488·51 enrolled

Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)

Terminated·UUniversity of Miami·Phase 2·NCT00450385·57 enrolled

A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL

Terminated·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1/2·NCT01483690·23 enrolled

Show 1 more trial

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

Recruiting·CC17 Council·Phase 1·NCT06942039·15 enrolled

Refractory Solid Tumors3 trials

Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors

Suspended·NNational Cancer Institute (NCI)·Phase 1/2·NCT04890093·64 enrolled

Metformin in Children With Relapsed or Refractory Solid Tumors

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT01528046·26 enrolled

VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 1/2·NCT04796012·23 enrolled

Neuroblastoma3 trials

A Study of N9 Chemotherapy in Children With Neuroblastoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04947501·26 enrolled

High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

Recruiting·SSt. Anna Kinderkrebsforschung·Phase 3·NCT01704716·3,300 enrolled

Therapy for Children With Advanced Stage Neuroblastoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT01857934·153 enrolled

Newly Diagnosed3 trials

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

Recruiting·CChildren's Oncology Group·Phase 2·NCT04322318·256 enrolled

First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL

Completed·TThe Catholic University of Korea·Phase 2·NCT01004497·51 enrolled

Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT04835870·78 enrolled

Hematologic Malignancies2 trials

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Recruiting·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1·NCT05476770·54 enrolled

Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT00718757·4 enrolled

Relapsed or Refractory2 trials

Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults

Terminated·—·Phase 2·NCT02535806·2 enrolled

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Recruiting·—·Phase 1/2·NCT06709495·63 enrolled

Glioma2 trials

A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas

Completed·JJulie Krystal·Phase 1/2·NCT01837862·36 enrolled

Modified CV Regimen in Optic Pathway Glioma

Recruiting·—·Phase 2·NCT05278715·75 enrolled

B-cell acute lymphoblastic leukemia2 trials

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

Completed·UUniversity of Washington·Phase 1·NCT03991884·24 enrolled

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02101853·669 enrolled

Ewing sarcoma2 trials

Irinotecan and Temozolomide for Ewing Sarcoma

Unknown status·PPeking University People's Hospital·Phase 2·NCT03359005·60 enrolled

Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01864109·83 enrolled

Stem Cell Transplant2 trials

Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00051311·62 enrolled

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00074490·442 enrolled

Pediatric Solid Tumors2 trials

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

Recruiting·TTheodore Laetsch·Phase 1/2·NCT06721689·59 enrolled

A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors

Completed·—·Phase 1·NCT00786669·13 enrolled

Rhabdomyosarcoma2 trials

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

Recruiting·CChildren's Oncology Group·Phase 3·NCT05304585·205 enrolled

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

Recruiting·UUniversity of Birmingham·Phase 1/2·NCT04625907·1,672 enrolled

DLBCL2 trials

Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A

Completed· Roche logo

Roche·Phase 3·NCT02406092·139 enrolled

R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL

Unknown status·NNanfang Hospital, Southern Medical University·Phase 3·NCT03018626·402 enrolled

Induction Chemotherapy2 trials

Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL

Completed·—·Phase 1·NCT01523977·22 enrolled

Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL

Unknown status·EEuropean Mantle Cell Lymphoma Network·Phase 3·NCT00209209·570 enrolled

Lenalidomide1 trial

Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 1/2·NCT04432714·81 enrolled

Children1 trial

A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02677116·68 enrolled

Lymphoblastic Lymphoma1 trial

NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT01451515·23 enrolled

Age1 trial

HD11 for Intermediate Stages

Completed·UUniversity of Cologne·Phase 3·NCT00264953·1,395 enrolled

Macroglobulinemia1 trial

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia

Terminated·EEastern Cooperative Oncology Group·Phase 2·NCT00060346·16 enrolled

Real-world Study1 trial

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

Recruiting·RRuijin Hospital··NCT05899621·332 enrolled

Langerhans Cell Histiocytosis1 trial

Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis

Recruiting·WWest China Second University Hospital·N/A·NCT07431060·120 enrolled

Multiple Myeloma1 trial

Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma

Completed·OOhio State University Comprehensive Cancer Center·Phase 2·NCT00201695·12 enrolled

Relapsed/Refractory1 trial

Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL

Completed·—·Phase 1·NCT03349281·6 enrolled

Central Nervous System Lymphoma1 trial

Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 2·NCT01399372·91 enrolled

Olverembatinib1 trial

Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL

Completed·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05594784·79 enrolled

Chidamide1 trial

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03564704·80 enrolled

Immune Thrombocytopenia1 trial

Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia

Completed·—·Phase 4·NCT03229746·40 enrolled

Toxicity1 trial

CHildren Treated With Vincristine: A Trial Regarding Pharmacokinetics, DNA And Toxicity of Targeted Therapy In Pediatric Oncology Patients.

Unknown status·—·Phase 4·NCT05844670·100 enrolled

Brentuximab Vedotin1 trial

A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms

Completed· Pfizer logo

Pfizer·Phase 1·NCT01309789·39 enrolled

Richter Transformation1 trial

Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial

Not yet recruiting·SSWOG Cancer Research Network·Phase 3·NCT07220187·102 enrolled

Randomized1 trial

Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial

Recruiting·FFei Li·Phase 2·NCT06700798·90 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06387121·53 enrolled

Hodgkins lymphoma1 trial

Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma

Completed·UUniversity of Cologne·Phase 2·NCT00284271·65 enrolled

Recurrent Sarcoma1 trial

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

Recruiting·MM.D. Anderson Cancer Center·N/A·NCT04199026·20 enrolled

Adult Acute Lymphoblastic Leukemia1 trial

High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)

Unknown status·JJapan Adult Leukemia Study Group·Phase 3·NCT00131027·240 enrolled

EBV-Positive DLBCL, Nos1 trial

Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT04181489·55 enrolled

Wilms tumor1 trial

Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)

Recruiting·CCentre Oscar Lambret·Phase 1/2·NCT05384821·28 enrolled

CHOP1 trial

Ph II CHOP+Velcade in Mediastinal LBCL

Terminated·—·Phase 2·NCT00361621·3 enrolled

B-cell Malignancies1 trial

Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies

Completed·—·Phase 1·NCT01760226·4 enrolled

Advanced Solid Tumors1 trial

A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1·NCT00960063·4 enrolled

Desmoplastic Small Round Cell Tumor1 trial

Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT01946529·24 enrolled

Richter's Syndrome1 trial

A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome

Recruiting·UUniversity of Birmingham·Phase 2·NCT03899337·105 enrolled

Ependymoma1 trial

Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT01096368·479 enrolled

Retinoblastoma1 trial

Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma

Terminated·UUniversity of California, San Francisco·Phase 1·NCT02116959·6 enrolled

Unilateral Retinoblastoma1 trial

Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)

Active, not recruiting·IInstitut Curie·Phase 2·NCT02870907·195 enrolled

Relapsed/Refractory B-cell ALL1 trial

Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL

Active, not recruiting·UUniversity of Virginia·Phase 1·NCT03962465·36 enrolled

Infants1 trial

Vincristine Pharmacokinetics in Infants

Active, not recruiting·CChildren's Oncology Group··NCT05359237·83 enrolled

B-cell Lymphoid Malignancies1 trial

Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies

Active, not recruiting·MMedical College of Wisconsin·Phase 1·NCT05270057·11 enrolled

Advanced Stage1 trial

HD12 for Advanced Stages

Completed·UUniversity of Cologne·Phase 3·NCT00265031

Gestational Trophoblastic Tumor1 trial

Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor

Unknown status·WWeiguo Lv·Phase 3·NCT02639650·214 enrolled

Primitive Neuroectodermal Tumor1 trial

Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor

Completed·SSt. Jude Children's Research Hospital·Phase 3·NCT00085202·416 enrolled

Safety and Efficacy1 trial

Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03283202·35 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

ONCOVIN

NDA NDA014103

Aug 9, 2012

MARQIBO KIT

NDA NDA202497

Sources

References

[1]
ClinicalTrials.gov — 436 trial records for Vincristine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Oncovin drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Vincristine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Vincristine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA202497). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Tubulin Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Eli Lilly

Oncovin

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Lymphoma45 trials

Acute Lymphoblastic Leukemia35 trials

Diffuse Large B-Cell Lymphoma18 trials

Mantle Cell Lymphoma8 trials

Treatment7 trials

Follicular Lymphoma6 trials

Leukemia6 trials

Medulloblastoma4 trials

Chemotherapy4 trials

Refractory Solid Tumors3 trials

Neuroblastoma3 trials

Newly Diagnosed3 trials

Hematologic Malignancies2 trials

Relapsed or Refractory2 trials

Glioma2 trials

B-cell acute lymphoblastic leukemia2 trials

Ewing sarcoma2 trials

Stem Cell Transplant2 trials

Pediatric Solid Tumors2 trials

Rhabdomyosarcoma2 trials

DLBCL2 trials

Induction Chemotherapy2 trials

Lenalidomide1 trial

Children1 trial

Lymphoblastic Lymphoma1 trial

Age1 trial

Macroglobulinemia1 trial

Real-world Study1 trial

Langerhans Cell Histiocytosis1 trial

Multiple Myeloma1 trial

Relapsed/Refractory1 trial

Central Nervous System Lymphoma1 trial

Olverembatinib1 trial

Chidamide1 trial

Immune Thrombocytopenia1 trial

Toxicity1 trial

Brentuximab Vedotin1 trial

Richter Transformation1 trial

Randomized1 trial

Efficacy and Safety1 trial

Hodgkins lymphoma1 trial

Recurrent Sarcoma1 trial

Adult Acute Lymphoblastic Leukemia1 trial

EBV-Positive DLBCL, Nos1 trial

Wilms tumor1 trial

CHOP1 trial

B-cell Malignancies1 trial

Advanced Solid Tumors1 trial

Desmoplastic Small Round Cell Tumor1 trial

Richter's Syndrome1 trial

Ependymoma1 trial

Retinoblastoma1 trial

Unilateral Retinoblastoma1 trial

Relapsed/Refractory B-cell ALL1 trial

Infants1 trial

B-cell Lymphoid Malignancies1 trial

Advanced Stage1 trial

Gestational Trophoblastic Tumor1 trial

Primitive Neuroectodermal Tumor1 trial

Safety and Efficacy1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News